Merck


Two are better than one

05/08/22 -"Merck reported another estimate-beating quarter. We hope investors will not be too upset when Merck’s performance no longer meets expectations. This might take quite a while as a second driver has ..."

Pages
78
Language
English
Published on
05/08/22
You may also be interested by these reports :
17/07/25
The Q2 sales growth, despite being impacted by adverse FX movements, impressed the markets. Both the segments contributed healthily to the quarterly ...

17/07/25
Q2 results were somewhat ahead of expectations, supported by healthy momentum across focus areas. Management also raised its full-year profitability ...

14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...

14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO